This week, STAT held a webinar entitled "What to Expect in Biotech 2018." The broadcast was hosted by Adam Feurstein, a senior biotech reporter, and Damian Garde, a national biotech reporter. The goal of the webinar was to provide a framework of the themes that are likely to shape the biotech sector in the coming year, as well to provide a look at biotech stocks in 2018.
This week, STAT held a webinar entitled “What to Expect in Biotech in 2018.” The broadcast was hosted by Adam Feurstein, a senior biotech reporter, and Damian Garde, a national biotech reporter. The goal of the webinar was to provide a framework of the themes that are likely to shape the biotech sector in the coming year, as well to provide a look at biotech stocks in 2018.
Garde highlighted the strides that both FDA Commissioner Scott Gottlieb, MD, and the FDA itself made in 2017 to expedite drug approvals and provide a more efficient, streamlined drug development process. Garde noted that it will be important to watch certain drugs after they’ve received expedited approval to make sure that drug efficacy or safety is still maintained through this quicker process.
Feurstein discussed potential upcoming FDA drug approvals throughout the year that could affect the biotech market, including:
According to a J.P. Morgan poll, 60% of investor respondents expect the biotech sector to outperform the broader market in 2018, and 84% expect an increase in mergers and acquisitions.
Presenters briefly mentioned biosimilars in the broadcast, stating that they’re here to stay, and companies that are making reference products will have to become innovative to keep up with the expected cost-savings from biosimilars, once more come to market.
As far as how the new tax reform bill could affect biotech companies, STAT believes that the increase in cash savings could result in either more mergers and acquisitions, or stock share buybacks later this year. According to the webcast, Amgen, Gilead Sciences, and Merck all hold more than $20 billion overseas.
The presentation closed with some drug launches and clinical trials to watch this year:
Drug launches:
Clinical Trials:
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.